PE20181296A1 - CRYSTALLINE FORM OF 2- (2,6-DICHLOROPHENYL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTIL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETHANONE FOR THE TREATMENT OF PARKINSON'S DISEASE - Google Patents
CRYSTALLINE FORM OF 2- (2,6-DICHLOROPHENYL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTIL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETHANONE FOR THE TREATMENT OF PARKINSON'S DISEASEInfo
- Publication number
- PE20181296A1 PE20181296A1 PE2018000570A PE2018000570A PE20181296A1 PE 20181296 A1 PE20181296 A1 PE 20181296A1 PE 2018000570 A PE2018000570 A PE 2018000570A PE 2018000570 A PE2018000570 A PE 2018000570A PE 20181296 A1 PE20181296 A1 PE 20181296A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- crystalline form
- dihydroisoquinolin
- ethanone
- dichlorophenyl
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- -1 2,6-DICHLOROPHENYL Chemical class 0.000 title 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- XHCSBQBBGNQINS-DOTOQJQBSA-N 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone Chemical compound N1([C@H](C2=CC=CC(CCC(C)(C)O)=C2C[C@@H]1CO)C)C(=O)CC1=C(Cl)C=CC=C1Cl XHCSBQBBGNQINS-DOTOQJQBSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a una forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona y composiciones farmaceuticas que comprenden a dicha forma cristalina. Dichos compuestos son moduladores alostericos positivos (MAP) del receptor de dopamina 1 (D1) y son utiles para el tratamiento de la enfermedad de Alzheimer, Parkinson, entre otrosRefers to a crystalline form of 2- (2,6-dichlorophenyl) -1 - [(1S, 3R) -3- (hydroxymethyl) -5- (3-hydroxy-3-methylbutyl) -1-methyl-3, 4-dihydroisoquinolin-2 (1H) -yl] ethanone and pharmaceutical compositions comprising said crystalline form. These compounds are positive allosteric modulators (MAP) of the dopamine 1 (D1) receptor and are useful for the treatment of Alzheimer's disease, Parkinson's disease, among others.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245391P | 2015-10-23 | 2015-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181296A1 true PE20181296A1 (en) | 2018-08-07 |
Family
ID=57233858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000570A PE20181296A1 (en) | 2015-10-23 | 2016-10-18 | CRYSTALLINE FORM OF 2- (2,6-DICHLOROPHENYL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTIL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETHANONE FOR THE TREATMENT OF PARKINSON'S DISEASE |
Country Status (13)
| Country | Link |
|---|---|
| CN (1) | CN108137506A (en) |
| AR (1) | AR106332A1 (en) |
| AU (1) | AU2016341115A1 (en) |
| CA (1) | CA2999332A1 (en) |
| DO (1) | DOP2018000103A (en) |
| EA (1) | EA201890525A1 (en) |
| EC (1) | ECSP18030976A (en) |
| IL (1) | IL257872A (en) |
| MX (1) | MX2018004794A (en) |
| PE (1) | PE20181296A1 (en) |
| PH (1) | PH12018500859A1 (en) |
| TW (1) | TW201725199A (en) |
| WO (1) | WO2017070068A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI725408B (en) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | Dopamine d1 receptor positive allosteric modulators |
| MD3897578T2 (en) | 2018-12-18 | 2025-04-30 | Lilly Co Eli | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| TWI825323B (en) * | 2019-06-18 | 2023-12-11 | 美商美國禮來大藥廠 | Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone |
| AU2022234744B2 (en) * | 2021-03-08 | 2025-06-26 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| AU2022234226B2 (en) * | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
| CN113264926A (en) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | Co-crystal of vitexin and reserpine and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| EP2125741A1 (en) * | 2007-03-01 | 2009-12-02 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| JO3316B1 (en) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | 3,4-dihydroisoquinolin-2(1h)-yl compounds |
-
2016
- 2016-10-13 AR ARP160103122A patent/AR106332A1/en unknown
- 2016-10-14 TW TW105133203A patent/TW201725199A/en unknown
- 2016-10-18 EA EA201890525A patent/EA201890525A1/en unknown
- 2016-10-18 MX MX2018004794A patent/MX2018004794A/en unknown
- 2016-10-18 PE PE2018000570A patent/PE20181296A1/en not_active Application Discontinuation
- 2016-10-18 CN CN201680061907.6A patent/CN108137506A/en active Pending
- 2016-10-18 AU AU2016341115A patent/AU2016341115A1/en not_active Abandoned
- 2016-10-18 WO PCT/US2016/057447 patent/WO2017070068A1/en not_active Ceased
- 2016-10-18 CA CA2999332A patent/CA2999332A1/en not_active Abandoned
-
2018
- 2018-03-05 IL IL257872A patent/IL257872A/en unknown
- 2018-04-20 EC ECIEPI201830976A patent/ECSP18030976A/en unknown
- 2018-04-20 PH PH12018500859A patent/PH12018500859A1/en unknown
- 2018-04-20 DO DO2018000103A patent/DOP2018000103A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2999332A1 (en) | 2017-04-27 |
| AU2016341115A1 (en) | 2018-04-12 |
| CN108137506A (en) | 2018-06-08 |
| DOP2018000103A (en) | 2018-10-31 |
| MX2018004794A (en) | 2018-06-19 |
| ECSP18030976A (en) | 2018-05-31 |
| AR106332A1 (en) | 2018-01-03 |
| TW201725199A (en) | 2017-07-16 |
| PH12018500859A1 (en) | 2018-10-29 |
| EA201890525A1 (en) | 2018-09-28 |
| WO2017070068A1 (en) | 2017-04-27 |
| IL257872A (en) | 2018-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181296A1 (en) | CRYSTALLINE FORM OF 2- (2,6-DICHLOROPHENYL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTIL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETHANONE FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| CL2016002812A1 (en) | Use of 3-2,3,5,6-tetrafluoro-3-trifluoromethoxy-biphenyl-4-ylcarbamoyl-thiophene-2-carboxylic acid to prepare a medicament useful for treating an eye disease that is uveitis, dry eye or caused by a adenovirus composition formulation. | |
| CL2019001978A1 (en) | 5-methyl-1,2,4-oxadiazol-3-yl compounds. | |
| PE20152032A1 (en) | 3,4-DIHYDROISOQUINOLIN-2 (1H) -IL COMPOUNDS | |
| PE20180501A1 (en) | BICYCLE BEDS AND METHODS OF USING THEM | |
| CL2017001426A1 (en) | New compounds of 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections. | |
| CL2015000578A1 (en) | Compound n- (2- (6-fluoro-1-h-indol-3-yl) ethyl) -3- (2,2,3,3-tetrafluoropropoxy) benzylamine or its salt, 5-ht6 receptor antagonist; pharmaceutical composition; Use in the treatment of Alzheimer's disease. | |
| JP2014221779A5 (en) | ||
| MX375639B (en) | SUBSTITUTED HETEROCYCHYL DERIVATIVES AS CDK INHIBITORS | |
| EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EP2916742A4 (en) | DYNAMIC AXIAL NAIL FOR THE INTRAMEDULAR TREATMENT OF LONG BONE FRACTURES | |
| CL2019002900A1 (en) | Benzoazepine analogs as bruton tyrosine kinase inhibitors. | |
| EA201691853A1 (en) | AGONISTS OF MUSCARINE RECEPTORS | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| PE20141200A1 (en) | FORMULATION OF A CAPSULE INCLUDING MONTELUKAST AND LEVOCETIRIZINE | |
| CL2015003195A1 (en) | Purine derivatives as cb2 receptor agonists. | |
| CL2015000559A1 (en) | Compounds derived from 2-oxo-2,3-dihydro-indoles; its process of obtaining; pharmaceutical composition and combination that includes them; and its use for the treatment of CNS disorders that are positive or negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, Alzheimer's disease, Parkinson's disease, among others. | |
| CL2016002238A1 (en) | Compounds derived from 3- (5-oxo-4,5-dihydro-1h-tetrazol-1-yl) -5,6-dihydropyridin-2 (1h) -one substituted with tetrazolone, monocylglycerol acyltransferase 2 (mgat2) inhibitors; pharmacological compositions; Useful for treating diabetes, hypeglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, non-alcoholic fatty liver disease, retinopathy, among others. | |
| CL2015003196A1 (en) | Pyrrolo [2,3-d] pyrimidine derivatives as cb2 receptor agonists. | |
| EA201591649A1 (en) | COMPOSITIONS WITH ORGANIC COMPOUNDS | |
| EA201691160A1 (en) | ANTAGONISTS S1P3 | |
| CL2020000601A1 (en) | Pharmaceutical composition. | |
| CL2015001881A1 (en) | Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition. | |
| EA201892341A1 (en) | POLYMORPHIC FORMS 3- [2-BUTYL-1- (2-DIETHYLAMINOETHYL) -1H-BENZOIMIDAZOL-5-IL] -N-HYDROXYACRYLAMIDE AND THEIR APPLICATION | |
| PE20170926A1 (en) | LOW DOSE A2A ANTAGONIST FOR THE TREATMENT OF ADHD AND PARKINSON'S DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |